

## HR 6948

To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to promulgate rules to update certain regulations relating to human cells, tissues, and cellular and tissue-based products, and for other purposes.

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Mar 7, 2022

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Mar 8, 2022)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/6948>

### Sponsor

**Name:** Rep. Crenshaw, Dan [R-TX-2]

**Party:** Republican • **State:** TX • **Chamber:** House

### Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Burgess, Michael C. [R-TX-26]	R · TX		Mar 7, 2022

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 8, 2022

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

*No related bills are listed.*

### Summary (as of Mar 7, 2022)

This bill requires the Food and Drug Administration to update its regulations relating to the manufacture of human cells, tissue, and cellular and tissue-based products (HCT/Ps), including an update to the definition of *minimal manipulation*. (The regulations are commonly referred to as the *tissue rules*; HCT/Ps that are *minimally manipulated* and meet other criteria are not regulated as drugs, devices, or biologics and therefore are not subject to premarket review.)

### Actions Timeline

- **Mar 8, 2022:** Referred to the Subcommittee on Health.
- **Mar 7, 2022:** Introduced in House
- **Mar 7, 2022:** Referred to the House Committee on Energy and Commerce